Price T Rowe Associates Inc Aadi Bioscience, Inc. Transaction History

Price T Rowe Associates Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$1.97 - $5.41 $394,000 - $1.08 Million	-200,000 Reduced 94.93%	10,692 $22,000
Q3 2023 Nov 14, 2023	SELL	$4.84 - $7.13 $85,692 - $126,236	-17,705 Reduced 7.75%	210,692 $1.02 Million
Q2 2023 Aug 14, 2023	SELL	$6.84 - $8.56 $63,830 - $79,881	-9,332 Reduced 3.93%	228,397 $1.56 Million
Q1 2023 May 15, 2023	SELL	$6.85 - $13.0 $51,470 - $97,682	-7,514 Reduced 3.06%	237,729 $1.72 Million
Q4 2022 Feb 14, 2023	SELL	$11.99 - $14.5 $72,371 - $87,522	-6,036 Reduced 2.4%	245,243 $3.15 Million
Q3 2022 Nov 14, 2022	BUY	$12.03 - $14.22 $48,613 - $57,463	4,041 Added 1.63%	251,279 $3.55 Million
Q2 2022 Aug 15, 2022	SELL	$11.57 - $17.92 $2.18 Million - $3.38 Million	-188,713 Reduced 43.29%	247,238 $3.05 Million
Q1 2022 May 16, 2022	SELL	$16.65 - $24.97 $1.21 Million - $1.82 Million	-72,941 Reduced 14.33%	435,951 $7.4 Million
Q4 2021 Feb 14, 2022	BUY	$19.32 - $29.02 $836,420 - $1.26 Million	43,293 Added 9.3%	508,892 $12.3 Million
Q3 2021 Nov 15, 2021	BUY	$25.52 - $41.85 $11.9 Million - $19.5 Million	465,599 New	465,599 $13 Million

12.6M

23.8K

Ticker AADI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,016,800
Market Cap $78.4M
Description
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.